Q32 Bio Inc. (Nasdaq: QTTB), a US-based clinical stage biotechnology company, announced on Monday that it is joining the Russell 3000 Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the US market opening effective 1 July 2024.
Investment managers and institutional investors use Russell indexes for index funds and as benchmarks for active investment strategies. Lee Kalowski, Q32 Bio president and chief financial officer, said, 'We are pleased to be included in the Russell 3000 Index as we approach our anticipated milestones, progress our pipeline for severe autoimmune and inflammatory diseases, and continue to expand our shareholder base.'
Dragonfly Therapeutics names new chief financial officer
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
BioSenic expands US patent portfolio for ATO use in sepsis treatment
BenevolentAI and AstraZeneca collaboration leads to novel target for lupus
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Henlius and Organon report success of HLX14 Phase 3 study
Nobelpharma's inhaled use of Leukine receives Japanese regulatory approval to treat aPAP